Skip to main content

Table 1 Associations of SLC6A1 protein expression with various clinicopathological characteristics of PCa patients

From: Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer

Clinicopathological CharacteristicsIRS of SLC6A1 in our cohort (n, %)SLC6A1 expression in TCGA dataset
CaseLow (n = 11)High (n = 39)PCaseMean ± S.D.P
Age(years)
 < 66207(35.0)13(65.0)0.07035515.05 ± 13.760.995
 ≥ 66304(13.3)26(86.7)14315.04 ± 10.67
Gleason score
 <8316(19.4)25(80.6)0.56429212.47 ± 10.40< 0.001
 ≥ 8195(26.3)14(73.7)20618.69 ± 15.15
Clinical stage
 <T3A295(17.2)24(82.8)0.34019412.22 ± 10.25< 0.001
 ≥ T3A216(28.6)15(71.4)30416.85 ± 14.12
Metastasis
 No  41614.45 ± 12.070.059
 Yes  8218.09 ± 16.42
PSA failure
 No  43914.57 ± 12.690.042
 Yes  5918.62 ± 14.31
  1. Note: “–” No cases in our cohort